Study Focus:

EMPA-KIDNEY is based on insights previously obtained from the EMPA-REG OUTCOME trial. That landmark trial investigated the effect of empagliflozin on cardiovascular outcomes in adults with type 2 diabetes and established cardiovascular disease, compared with placebo. Approximately one-third of patients in the EMPA-REG OUTCOME trial also had established chronic kidney disease at baseline. A secondary exploratory endpoint of the study provided promising data relating to the reduction in the relative risk of new onset or worsening kidney disease. EMPA-KIDNEY is designed to further researchers’ understanding of that data.

Study Population:
5,000 adults with established chronic kidney disease, with and without diabetes.